Recent advances in targeted anti-vasculature therapy: the neuroblastoma model.
Novel anti-vasculature strategies that are emerging for the treatment of cancer and for the inhibition of angiogenesis may be a promising new tool for the adjuvant therapy of malignant tumours. Over the last fifteen years, several reports have been published concerning the relationship between tumour progression and angiogenesis in experimental models of neuroblastoma in vitro and in vivo. Moreover, a high vascular index in neuroblastoma correlates with poor prognosis, suggesting dependence of aggressive tumour growth on active angiogenesis. Here, we present an overview of the most recent advances in anti-vasculature therapy of neuroblastoma, and describe some preclinical results as well as future perspectives.
Pastorino
F
F
Experimental Therapy Unit, Laboratory of Oncology, G. Gaslini Children's Hospital, Largo G. Gaslini 5, 16148 Genoa, Italy. fabiopastorino@ospedale-gaslini.ge.it
Di Paolo
D
D
Loi
M
M
Becherini
P
P
Caffa
I
I
Zorzoli
A
A
Marimpietri
D
D
Carosio
R
R
Perri
P
P
Montaldo
P G
PG
Brignole
C
C
Pagnan
G
G
Ribatti
D
D
Allen
T M
TM
Ponzoni
M
M
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018450:Disease Progression; D016503:Drug Delivery Systems; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D009447:Neuroblastoma / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents